# Fondazione Michelangelo

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/fondazione-michelangelo/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 87 |
| Citations | 21,207 |
| City | Milan |
| Country | IT |
| Description | Fondazione Michelangelo is a research organisation in Milan, IT. OpenAlex records 155 works and 21,207 citations for it. |
| Homepage | http://www.fondazionemichelangelo.org/en/ |
| OpenAlex ID | https://openalex.org/I4210099045 |
| ROR ID | https://ror.org/014vaxq24 |
| Type | nonprofit |
| Works | 155 |

## University papers

Showing 12 of 15.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer](https://scholariq.org/papers/combination-chemotherapy-as-an-adjuvant-treatment-in-operable-breast-cancer/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)
- [Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More](https://scholariq.org/papers/primary-chemotherapy-to-avoid-mastectomy-in-tumors-with-diameters-of-three/)
- [Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.](https://scholariq.org/papers/paclitaxel-by-3-hour-infusion-in-combination-with-bolus-doxorubicin-in-women/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma](https://scholariq.org/papers/high-dose-chemotherapy-and-autologous-bone-marrow-transplantation-compared-with/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer](https://scholariq.org/papers/ten-year-experience-with-cmf-based-adjuvant-chemotherapy-in-resectable-breast/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.